Management ChangeApr 28, 2026, 04:23 PM
GRAIL CEO Ragusa Retires, Ofman Appointed; Galleri FDA PMA Submitted
AI Summary
GRAIL, Inc. announced that CEO Robert Ragusa will retire on June 1, 2026, and Dr. Joshua Ofman, current President, will succeed him as CEO. The company also completed the submission of its PMA for Galleri, the first multi-cancer early detection test, to the FDA. Additionally, GRAIL will hold its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders will vote on director elections and auditor ratification.
Key Highlights
- GRAIL CEO Robert Ragusa to retire June 1, 2026; Dr. Joshua Ofman appointed as new CEO.
- GRAIL completed PMA submission for Galleri, a multi-cancer early detection test, to the FDA.
- 2026 Annual Meeting of Stockholders scheduled for June 18, 2026.
- Shareholders to vote on election of Steven Mizell and Sarah Krevans as Class II Directors.
- Shareholders to ratify appointment of Ernst & Young LLP as independent auditor for 2026.
- Galleri aims to identify ~60% of cancers through screening, up from 14% today.
- Legislation passed allowing Medicare to pay for FDA-approved MCED tests.
- Upcoming data readouts from 140,000-person NHS Galleri Trial and 35,000-person PATHFINDER 2 study mid-year.